Early safety study of LY4174794 in otherwise healthy adults with obesity or overweight
Tests how safe LY4174794 is in healthy adults with obesity or overweight.
Plain-language title generated from the registry record
Registry title: A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Key facts
- Where
- Singapore, SingaporeSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07654972, who can take part
Where in Singapore
- Lilly Centre for Clinical PharmacologySingapore, SingaporeNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07654972
- Record updated
- 15 October 2026
- Original description
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it.Read full original descriptionShow less
A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it.
Participation in this study will last about 30 to 39 weeks (7 to 10 months).
Inclusion: Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease; Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m²; Have had a self-reported stable weight for 3 months prior to screening.
Exclusion: Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data; Is an individual of childbearing potential (IOCBP).